Skip to main content
. 2023 Oct 23;51(21):11634–11651. doi: 10.1093/nar/gkad907

Figure 1.

Figure 1.

BRD9 deficiency results in the instability of pluripotency in hESCs. (A) Transcript levels of pluripotency-associated genes in H1 hESCs treated with 10 μM I-BRD9 for 24 h in E8 medium, as determined by qPCR. (B) Western blot analysis of OCT4, NANOG and SOX2 protein levels in H1 hESCs treated with 10 μM I-BRD9 for 24 h in E8 medium, with glyceraldehyde phosphate dehydrogenase (GAPDH) as a loading control. (C–E) Transcript levels of OCT4 (C), NANOG (D) and SOX2 (E) in hESCs at the indicated passages treated or not with 10 μM I-BRD9 in E8 medium, as determined by qPCR. (F–H) Quantification of colony number (F) and morphology (G) of hESCs treated or not with I-BRD9 in E8 medium. Colonies were scored as undifferentiated (undiff.), mixed or differentiated (diff.) (H). (I) Transcript levels of pluripotency-associated genes in hESCs treated with 100 nM dBRD9-A for 48 h in E8 medium, as determined by qPCR. (J) Western blot analysis of BRD9, OCT4, NANOG and SOX2 protein levels in hESCs treated with 100 nM dBRD9-A for 48 h in E8 medium, with GAPDH as a loading control. (K) Transcript levels of pluripotency-associated genes in BRD9-depleted hESCs with BRD9 shRNA, as determined by qPCR.